NASDAQ:WVE WAVE Life Sciences Q3 2026 Earnings Date & Estimates $3.30 -0.16 (-4.48%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more. WAVE Life Sciences is scheduled to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from WAVE Life Sciences in Q3 2026WAVE Life Sciences is expected to post earnings of -$0.33 per share on revenue of $4.61 million. In the same quarter a year earlier WAVE Life Sciences reported -$0.32 per share on revenue of $7.61 million. WAVE Life Sciences last reported on July 30, 2026, posting -$0.34 per share and missing the -$0.2998 consensus estimate. WAVE Life Sciences has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.33Expected Revenue$4.61 millionPrior-Year EPS-$0.32Prior-Year Revenue$7.61 millionExpected Revenue Growth-39.4%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.34 (Missed by -$0.0403)Last Quarter Revenue$2.27 millionEPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report WAVE Life Sciences Q3 2026 Earnings FAQ When does WAVE Life Sciences report Q3 2026 earnings? WAVE Life Sciences (NASDAQ:WVE) is scheduled to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. What time is WAVE Life Sciences' Q3 2026 earnings call? WAVE Life Sciences' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for WAVE Life Sciences? Analysts expect WAVE Life Sciences to post earnings of -$0.33 per share for Q3 2026. How much revenue is WAVE Life Sciences expected to report? The consensus revenue estimate for WAVE Life Sciences is $4.61 million for Q3 2026. WAVE Life Sciences Earnings HeadlinesWAVE Life Sciences (NASDAQ:WVE) Reaches New 52-Week Low - Should You Sell?1 hour ago | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Liquidia Technologies (LQDA) and Abbott Laboratories (ABT)October 3, 2026 | theglobeandmail.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 12 at 1:00 AM | Weiss Ratings (Ad)Analysts Are Bullish on Top Healthcare Stocks: Johnson & Johnson (JNJ), Wave Life Sciences (WVE)October 3, 2026 | theglobeandmail.comWave Life Sciences Says FDA Feedback Supports Registrational Pathway for WVE-006October 1, 2026 | finance.yahoo.comWave Gains FDA Support For WVE-006 Registrational Pathway In AATDOctober 1, 2026 | rttnews.comSee More WAVE Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like WAVE Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on WAVE Life Sciences and other key companies, straight to your email. Email Address About WAVE Life SciencesWAVE Life Sciences (NASDAQ:WVE) is a clinical-stage biotechnology company developing RNA medicines for genetic and other serious diseases. The company uses its proprietary oligonucleotide and RNA-editing technologies to target disease-causing genetic instructions, with the goal of selectively correcting, reducing, or modifying RNA activity. Its development programs have included investigational therapies for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease. WAVE’s pipeline has featured RNA-editing candidates designed to make precise changes to RNA, as well as stereopure oligonucleotides intended to improve the activity and tolerability of RNA-based medicines. These candidates remain subject to clinical and regulatory evaluation. Founded in 2012, WAVE Life Sciences is headquartered in Lexington, Massachusetts, and has maintained operations in Singapore, supporting its research and development activities. The company’s chief executive officer is Paul Bolno, who has led WAVE since 2019. WAVE’s work is focused primarily on advancing therapies for patients with genetically driven diseases in global clinical and research settings.View WAVE Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
